{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:09:12Z","timestamp":1788314952662,"version":"build-2803163510"},"reference-count":112,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nuclear Medicine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1053\/j.semnuclmed.2024.05.012","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T03:31:11Z","timestamp":1719977471000},"page":"717-732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Radionuclide Imaging of Cardiac Amyloidosis: An Update and Future Aspects"],"prefix":"10.1053","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7725-9318","authenticated-orcid":false,"given":"Olivier F.","family":"Clerc","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5085-1397","authenticated-orcid":false,"given":"Shilpa","family":"Vijayakumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1462-1185","authenticated-orcid":false,"given":"Sharmila","family":"Dorbala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0001","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0002","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1161\/CIRCRESAHA.121.318187","article-title":"Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis","volume":"128","author":"Griffin","year":"2021","journal-title":"Circ Res"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0003","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1080\/13506129.2022.2147636","article-title":"Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"29","author":"Buxbaum","year":"2022","journal-title":"Amyloid"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0004","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1016\/j.jacc.2019.04.003","article-title":"Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review","volume":"73","author":"Ruberg","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0005","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jaccao.2021.08.009","article-title":"Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey","volume":"3","author":"Nativi-Nicolau","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0006","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.jacc.2016.06.053","article-title":"Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy","volume":"68","author":"Falk","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0007","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac Amyloidosis: Evolving Diagnosis and Management: A Scientific Statement From the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0008","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0009","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jaccao.2021.09.003","article-title":"Current Chemotherapy and Immune Therapy Treatment Strategies: JACC: CardioOncology State-of-the-Art Review","volume":"3","author":"Bianchi","year":"2021","journal-title":"JACC CardioOncol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0010","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0011","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004769","article-title":"TTR (Transthyretin) Stabilizers Are Associated With Improved Survival in Patients With TTR Cardiac Amyloidosis","volume":"11","author":"Rosenblum","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0012","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13506129.2018.1519507","article-title":"Diflunisal tolerability in transthyretin cardiac amyloidosis: a single center's experience","volume":"25","author":"Ikram","year":"2018","journal-title":"Amyloid"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0013","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1001\/jama.2013.283815","article-title":"Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial","volume":"310","author":"Berk","year":"2013","journal-title":"JAMA"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0014","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0015","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0016","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0017","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0018","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1056\/NEJMoa2107454","article-title":"CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis","volume":"385","author":"Gillmore","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0019","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2303765","article-title":"Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid","volume":"389","author":"Garcia-Pavia","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2305434","article-title":"Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy","volume":"390","author":"Gillmore","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0021","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0022","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1182\/blood.2020009039","article-title":"Phase 1a\/b study of monoclonal antibody CAEL-101 (11-1F4) in patients with AL amyloidosis","volume":"138","author":"Edwards","year":"2021","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0023","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2022019406","article-title":"Birtamimab plus standard of care in light chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial","volume":"142","author":"Gertz","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0024","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0025","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0026","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System","volume":"68","author":"Grogan","year":"2016","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0027","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1007\/s12350-019-01760-6","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging","volume":"26","author":"Dorbala","year":"2019","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0028","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1016\/j.echo.2022.06.006","article-title":"Practical Points for Echocardiography in Cardiac Amyloidosis","volume":"35","author":"Cuddy","year":"2022","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0029","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0030","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s12350-019-01761-5","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization","volume":"27","author":"Dorbala","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0031","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1182\/blood-2009-07-230722","article-title":"Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens","volume":"114","author":"Vrana","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0032","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1097\/PAS.0b013e3182263d74","article-title":"Strong transthyretin immunostaining: potential pitfall in cardiac amyloid typing","volume":"35","author":"Satoskar","year":"2011","journal-title":"Am J Surg Pathol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0033","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/jamacardio.2018.2093","article-title":"Geographic Disparities in Reported US Amyloidosis Mortality From 1979 to 2015: Potential Underdetection of Cardiac Amyloidosis","volume":"3","author":"Alexander","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0034","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1053\/j.semnuclmed.2020.01.001","article-title":"Multimodality Imaging in the Evaluation and Management of Cardiac Amyloidosis","volume":"50","author":"Khor","year":"2020","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0035","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1007\/s12350-015-0235-z","article-title":"Quantitative molecular imaging of cardiac amyloidosis: The journey has begun","volume":"23","author":"Dorbala","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0036","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.jcmg.2020.05.005","article-title":"Quantitative Bone-Avid Tracer SPECT\/CT for Cardiac Amyloidosis: A Crucial Step Forward","volume":"13","author":"Dorbala","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0037","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.120.247312","article-title":"Absolute Quantitation of Cardiac 99mTc-Pyrophosphate Using Cadmium-Zinc-Telluride-Based SPECT\/CT","volume":"62","author":"Dorbala","year":"2021","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0038","first-page":"1431","article-title":"Understanding the standardized uptake value, its methods, and implications for usage","volume":"45","author":"Thie","year":"2004","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0039","first-page":"1836","article-title":"SUV: standard uptake or silly useless value?","volume":"36","author":"Keyes","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0040","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1007\/s00259-014-2787-6","article-title":"Imaging cardiac amyloidosis: a pilot study using 18F-florbetapir positron emission tomography","volume":"41","author":"Dorbala","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0041","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.jcmg.2023.07.007","article-title":"Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir: A Pilot PET\/CT Study","volume":"16","author":"Clerc","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0042","doi-asserted-by":"crossref","unstructured":"Clerc OF, Datar Y, Cuddy SAM, et al. Prognostic value of left ventricular 18F-florbetapir uptake in systemic light-chain amyloidosis. JACC Cardiovasc Imaging. Published online July 10, 2024. http:\/\/doi.org\/10.1016\/j.jcmg.2024.05.002","DOI":"10.1016\/j.jcmg.2024.05.002"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0043","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jamacardio.2016.2839","article-title":"Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis","volume":"1","author":"Castano","year":"2016","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0044","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1056\/NEJMc1917321","article-title":"Epidemiologic and Survival Trends in Amyloidosis, 1987-2019","volume":"382","author":"Ravichandran","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0045","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0046","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0047","article-title":"Prevalence of Transthyretin Amyloid Cardiomyopathy in Heart Failure With Preserved Ejection Fraction","volume":"25","author":"AbouEzzeddine","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0048","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1002\/ehf2.13360","article-title":"Prevalence of transthyretin amyloidosis in patients with heart failure and no left ventricular hypertrophy","volume":"8","author":"Devesa","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0049","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jacc.2020.11.006","article-title":"Prevalence and Outcomes of Concomitant Aortic Stenosis and Cardiac Amyloidosis","volume":"77","author":"Nitsche","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0050","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"European Heart Journal"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0051","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ejhf.1742","article-title":"Carpal tunnel syndrome in cardiac amyloidosis: implications for early diagnosis and prognostic role across the spectrum of aetiologies","volume":"22","author":"Milandri","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0052","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.jacc.2022.06.026","article-title":"Screening for Cardiac Amyloidosis 5 to 15 Years After Surgery for Bilateral Carpal Tunnel Syndrome","volume":"80","author":"Westin","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0053","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","article-title":"DPD Quantification in Cardiac Amyloidosis: A Novel Imaging Biomarker","volume":"13","author":"Scully","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0054","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13550-021-00828-0","article-title":"Quantitative SPECT\/CT parameters of myocardial 99mTechnetium-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) uptake in suspected cardiac transthyretin amyloidosis","volume":"11","author":"Ben-Haim","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0055","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12350-022-02960-3","article-title":"Quantitative 99mTc-DPD-SPECT\/CT assessment of cardiac amyloidosis","volume":"30","author":"Kessler","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0056","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR Derived Extracellular Volume With Patisiran Indicates Cardiac Amyloid Regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0057","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/jead030","article-title":"Monitoring tafamidis treatment with quantitative SPECT\/CT in transthyretin amyloid cardiomyopathy","author":"Rettl","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0058","doi-asserted-by":"crossref","DOI":"10.1093\/ehjopen\/oead092","article-title":"Prognosis prediction in cardiac amyloidosis by cardiac magnetic resonance imaging: a systematic review with meta-analysis","volume":"3","author":"Boretto","year":"2023","journal-title":"Eur Heart J Open"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0059","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2022.02.048","article-title":"Prognostic Implications of Right Ventricular Systolic Dysfunction in Cardiac Amyloidosis","volume":"173","author":"Tjahjadi","year":"2022","journal-title":"The American Journal of Cardiology"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0060","doi-asserted-by":"crossref","DOI":"10.1093\/ehjci\/jead119.173","article-title":"Diagnostic and prognostic value of right ventricle uptake at 99m-PYP scintigraphy in patients with ATTR cardiac amyloidosis","volume":"24","author":"Glavam","year":"2023","journal-title":"European Heart Journal - Cardiovascular Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0061","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.123.066524","article-title":"Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy","volume":"149","author":"Porcari","year":"2024","journal-title":"Circulation"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0062","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1053\/j.semnuclmed.2012.07.001","article-title":"Development of positron emission tomography \u03b2-amyloid plaque imaging agents","volume":"42","author":"Mathis","year":"2012","journal-title":"Semin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0063","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2967\/jnumed.111.102053","article-title":"In vivo visualization of amyloid deposits in the heart with 11C-PIB and PET","volume":"54","author":"Antoni","year":"2013","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0064","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jcmg.2014.09.018","article-title":"11C-Pittsburgh B PET imaging in cardiac amyloidosis","volume":"8","author":"Lee","year":"2015","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0065","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/s12350-015-0149-9","article-title":"Accurate analysis and visualization of cardiac (11)C-PIB uptake in amyloidosis with semiautomatic software","volume":"23","author":"Kero","year":"2016","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0066","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12350-016-0638-5","article-title":"Positron emission tomography (PET) utilizing Pittsburgh compound B (PIB) for detection of amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR)","volume":"25","author":"Pilebro","year":"2018","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0067","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3389\/fcvm.2015.00023","article-title":"A Routine PET\/CT Protocol with Streamlined Calculations for Assessing Cardiac Amyloidosis Using (18)F-Florbetapir","volume":"2","author":"Osborne","year":"2015","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0068","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCIMAGING.114.002954","article-title":"18F-Florbetapir Binds Specifically to Myocardial Light Chain and Transthyretin Amyloid Deposits: Autoradiography Study","volume":"8","author":"Park","year":"2015","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0069","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1080\/13506129.2018.1552852","article-title":"A pilot study demonstrating cardiac uptake with 18F-florbetapir PET in AL amyloidosis patients with cardiac involvement","volume":"25","author":"Manwani","year":"2018","journal-title":"Amyloid"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0070","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2967\/jnumed.118.221770","article-title":"Early Detection of Multiorgan Light-Chain Amyloidosis by Whole-Body 18F-Florbetapir PET\/CT","volume":"60","author":"Ehman","year":"2019","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0071","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1007\/s00259-019-04627-7","article-title":"Quantitative [18F]florbetapir PET\/CT may identify lung involvement in patients with systemic AL amyloidosis","volume":"47","author":"Khor","year":"2020","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0072","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2967\/jnumed.115.169870","article-title":"Cardiac Amyloid Imaging with 18F-Florbetaben PET: A Pilot Study","volume":"57","author":"Law","year":"2016","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0073","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s00259-019-04290-y","article-title":"Detection of cardiac amyloidosis with 18F-Florbetaben-PET\/CT in comparison to echocardiography, cardiac MRI and DPD-scintigraphy","volume":"46","author":"Kircher","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0074","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1007\/s12149-019-01372-7","article-title":"Amyloid PET imaging in cardiac amyloidosis: a pilot study using 18F-flutemetamol positron emission tomography","volume":"33","author":"Dietemann","year":"2019","journal-title":"Ann Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s12350-018-1365-x","article-title":"Cardiac amyloidosis imaging with amyloid positron emission tomography: A systematic review and meta-analysis","volume":"27","author":"Kim","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0076","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jcmg.2020.02.023","article-title":"Diagnostic Accuracy of [11C]PIB Positron Emission Tomography for Detection of Cardiac Amyloidosis","volume":"13","author":"Rosengren","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0077","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.830572","article-title":"Diagnostic Value of 11C-PIB PET\/MR in Cardiac Amyloidosis","volume":"9","author":"Bi","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0078","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s12350-018-1349-x","article-title":"Quantification of 11C-PIB kinetics in cardiac amyloidosis","volume":"27","author":"Kero","year":"2020","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0079","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1080\/13506129.2020.1798223","article-title":"Non-invasive detection and differentiation of cardiac amyloidosis using 99mTc-pyrophosphate scintigraphy and 11C-Pittsburgh compound B PET imaging","volume":"27","author":"Takasone","year":"2020","journal-title":"Amyloid"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/path.1759","article-title":"Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology","volume":"206","author":"Bergstr\u00f6m","year":"2005","journal-title":"J Pathol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0081","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/path.2411","article-title":"Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis","volume":"216","author":"Ihse","year":"2008","journal-title":"J Pathol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0082","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jns.2009.07.028","article-title":"Distinct characteristics of amyloid deposits in early- and late-onset transthyretin Val30Met familial amyloid polyneuropathy","volume":"287","author":"Koike","year":"2009","journal-title":"J Neurol Sci"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0083","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jns.2018.09.011","article-title":"The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: An ultrastructural study","volume":"394","author":"Koike","year":"2018","journal-title":"J Neurol Sci"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0084","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","article-title":"(99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis","volume":"121","author":"Pilebro","year":"2016","journal-title":"Ups J Med Sci"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0085","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jcmg.2020.05.031","article-title":"[18F]-Florbetaben PET\/CT for Differential Diagnosis Among Cardiac Immunoglobulin Light Chain, Transthyretin Amyloidosis, and Mimicking Conditions","volume":"14","author":"Genovesi","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0086","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/13506129.2020.1760237","article-title":"Quantification of cardiac amyloid with [18F]Flutemetamol in patients with V30M hereditary transthyretin amyloidosis","volume":"27","author":"M\u00f6ckelind","year":"2020","journal-title":"Amyloid"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0087","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s12350-020-02363-2","article-title":"18F-flutemetamol positron emission tomography in cardiac amyloidosis","volume":"29","author":"Papathanasiou","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0088","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/RLU.0000000000004411","article-title":"18 F-Flutemetamol PET\/CT for Transthyretin Amyloid Cardiomyopathy\u202f: Timing Matters","volume":"47","author":"Han","year":"2022","journal-title":"Clin Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0089","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/13506129.2022.2141623","article-title":"The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid deposits: a post-mortem histofluorescence analysis","volume":"30","author":"Abrahamson","year":"2023","journal-title":"Amyloid"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0090","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jcmg.2020.02.025","article-title":"Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis: Redefining Early Disease?","volume":"13","author":"Cuddy","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0091","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.693194","article-title":"Pilot Study of F18-Florbetapir in the Early Evaluation of Cardiac Amyloidosis","volume":"8","author":"Sperry","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0092","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1007\/s12350-019-01961-z","article-title":"Reproducibility and Repeatability of Assessment of Myocardial Light Chain Amyloidosis Burden Using 18F-Florbetapir PET\/CT","volume":"28","author":"Nodoushani","year":"2021","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0093","first-page":"jead350","article-title":"Quantification of Right Ventricular Amyloid Burden with 18F-florbetapir PET\/CT and its Association with Right Ventricular Dysfunction and Outcomes in Light-Chain Amyloidosis","author":"Datar","year":"2024","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0094","doi-asserted-by":"crossref","first-page":"e26021","DOI":"10.1016\/j.heliyon.2024.e26021","article-title":"Kinetic analysis of cardiac dynamic 18F-Florbetapir PET in healthy volunteers and amyloidosis patients: A pilot study","volume":"10","author":"Wang","year":"2024","journal-title":"Heliyon"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0095","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s10554-021-02190-7","article-title":"Deep-learning-based cardiac amyloidosis classification from early acquired pet images","volume":"37","author":"Santarelli","year":"2021","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0096","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s12350-021-02608-8","article-title":"Cardiac amyloidosis characterization by kinetic model fitting on [18F]florbetaben PET images","volume":"29","author":"Santarelli","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0097","doi-asserted-by":"crossref","first-page":"E586","DOI":"10.1073\/pnas.1103247108","article-title":"In vivo molecular imaging of peripheral amyloidosis using heparin-binding peptides","volume":"108","author":"Wall","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0098","doi-asserted-by":"crossref","first-page":"7657","DOI":"10.3390\/molecules20057657","article-title":"Preclinical Validation of the Heparin-Reactive Peptide p5+14 as a Molecular Imaging Agent for Visceral Amyloidosis","volume":"20","author":"Wall","year":"2015","journal-title":"Molecules"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0099","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s11307-015-0914-9","article-title":"Tc-99m Radiolabeled Peptide p5\u202f+\u202f14 is an Effective Probe for SPECT Imaging of Systemic Amyloidosis","volume":"18","author":"Kennel","year":"2016","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0100","doi-asserted-by":"crossref","first-page":"22695","DOI":"10.1038\/srep22695","article-title":"Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis","volume":"6","author":"Martin","year":"2016","journal-title":"Sci Rep"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0101","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.peptides.2014.07.024","article-title":"Dynamic PET and SPECT imaging with radioiodinated, amyloid-reactive peptide p5 in mice: A positive role for peptide dehalogenation","volume":"60","author":"Martin","year":"2014","journal-title":"Peptides"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0102","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11307-021-01681-2","article-title":"First in Human Evaluation and Dosimetry Calculations for Peptide 124I-p5+14-a Novel Radiotracer for the Detection of Systemic Amyloidosis Using PET\/CT Imaging","volume":"24","author":"Wall","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0103","doi-asserted-by":"crossref","first-page":"629","DOI":"10.3390\/ph16040629","article-title":"Clinical Confirmation of Pan-Amyloid Reactivity of Radioiodinated Peptide 124I-p5+14 (AT-01) in Patients with Diverse Types of Systemic Amyloidosis Demonstrated by PET\/CT Imaging","volume":"16","author":"Martin","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0104","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1016\/j.jcmg.2023.08.009","article-title":"Cardiac Amyloid Detection by PET\/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1\/2 Study","volume":"16","author":"Wall","year":"2023","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0105","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s12350-023-03267-7","article-title":"In the thick of it: hereditary cardiac amyloidosis identified by 124I-AT-01 PET imaging but not cardiac MRI or SPECT 99mTc pyrophosphate scintigraphy","volume":"30","author":"Smiley","year":"2023","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0106","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1275372","article-title":"Development and characterization of a prototypic pan-amyloid clearing agent - a novel murine peptide-immunoglobulin fusion","volume":"14","author":"Foster","year":"2023","journal-title":"Front Immunol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0107","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jacc.2019.11.037","article-title":"Pittsburgh B Compound Positron Emission Tomography in Patients With AL Cardiac Amyloidosis","volume":"75","author":"Lee","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0108","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.2967\/jnumed.121.263033","article-title":"Independent Prognostic Utility of 11 C-Pittsburgh Compound B PET in Patients with Light-Chain Cardiac Amyloidosis","volume":"63","author":"Choi","year":"2022","journal-title":"J Nucl Med"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0109","first-page":"1","article-title":"Reduction of cardiac AL amyloid deposition after complete response visualised by PiB-PET imaging","volume":"16","author":"Oguchi","year":"2022","journal-title":"Amyloid"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0110","first-page":"1","article-title":"Longitudinal PET\/CT imaging with iodine (124I) evuzamitide reveals organ response to plasma cell immunotherapy in a patient with AL amyloidosis","author":"Lands","year":"2023","journal-title":"Amyloid"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0111","doi-asserted-by":"crossref","DOI":"10.1016\/j.nuclcard.2024.101816","article-title":"Feasibility of 11C-Pittsburgh compound B positron emission tomography\/computed tomography for treatment monitoring with Tafamidis in a patient with transthyretin cardiac amyloidosis","author":"Fujioka","year":"2024","journal-title":"J Nucl Cardiol"},{"key":"10.1053\/j.semnuclmed.2024.05.012_bib0112","doi-asserted-by":"crossref","first-page":"20S","DOI":"10.2967\/jnumed.122.264866","article-title":"Molecular Imaging of Systemic and Cardiac Amyloidosis: Recent Advances and Focus on the Future","volume":"64","author":"Dorbala","year":"2023","journal-title":"J Nucl Med"}],"container-title":["Seminars in Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000539?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0001299824000539?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,16]],"date-time":"2024-08-16T12:55:45Z","timestamp":1723812945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0001299824000539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":112,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0001299824000539"],"URL":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.05.012","relation":{},"ISSN":["0001-2998"],"issn-type":[{"value":"0001-2998","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radionuclide Imaging of Cardiac Amyloidosis: An Update and Future Aspects","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nuclear Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semnuclmed.2024.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}